



## Treatment of Peripheral Vascular Disease – Present and Future

Guest Editors:

### **Dr. Jörn F Dopheide**

1. Department of Medicine I, Jena University Hospital, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany
2. Bern University Hospital, University of Bern, 3010 Bern, Switzerland
3. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), 6800 Feldkirch, Austria

### **Prof. Dr. Heinz Drexel**

1. Department for Internal Medicine, Hospital Bregenz, Bregenz, Austria
2. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria

Deadline for manuscript submissions:

**closed (27 December 2023)**

### **Message from the Guest Editors**

At present, cardiovascular disease still takes the highest death toll worldwide. Peripheral artery disease (PAD) patients suffer from a particularly poor prognosis. With this knowledge, efforts to reduce ischemic events and improve cardiovascular outcomes have been the driving force behind cardiovascular research in recent decades. One central strategy to improve cardiovascular outcomes is lipid lowering. For the time being, the most important drugs to reduce cholesterol still are statins. Next to statins, PCSK-9 inhibitors have already shown their benefit in PAD. Alternatively, non-statin lipid-lowering therapy, i.e. ezetimibe or bempedoic acid has yet to prove its value beyond combination. Another important field in the treatment of peripheral arterial disease is by influencing platelet aggregation and coagulation. This remains of great importance especially before, during and after vascular intervention or surgery. Finally, anticoagulation management especially in secondary prophylaxis of deep vein thrombosis and pulmonary embolism is a challenging task, especially in situations with the rare thrombophilic predisposition.





an Open Access Journal by MDPI

## Editors-in-Chief

**Prof. Dr. Emmanuel Andrès**

Internal Medicine Department,  
University Hospital Strasbourg,  
67081 Strasbourg, France

**Prof. Dr. Kent Doi**

Department of Emergency and  
Critical Care Medicine, The  
University of Tokyo, Tokyo, Japan

## Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's (JCM)* staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

## Contact Us

---

*Journal of Clinical Medicine* Editorial  
Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jcm](http://mdpi.com/journal/jcm)  
[jcm@mdpi.com](mailto:jcm@mdpi.com)  
[X@JCM\\_MDPI](https://twitter.com/JCM_MDPI)